Bridgewater Advisors Inc. bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 2,380 shares of the medical research company's stock, valued at approximately $1,366,000.
Other institutional investors also recently made changes to their positions in the company. BIP Wealth LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter valued at approximately $308,000. Compound Global Advisors LLC bought a new stake in Thermo Fisher Scientific during the second quarter worth approximately $50,000. Trifecta Capital Advisors LLC acquired a new stake in Thermo Fisher Scientific in the second quarter worth approximately $6,017,000. Everett Harris & Co. CA bought a new position in Thermo Fisher Scientific during the 2nd quarter valued at $7,916,000. Finally, Summit Global Investments acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at $634,000. 89.23% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
TMO has been the subject of several research analyst reports. Stifel Nicolaus set a $650.00 price objective on Thermo Fisher Scientific in a report on Wednesday, August 5th. KeyCorp reiterated an "overweight" rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, July 14th. Wolfe Research began coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 price objective on the stock. Finally, Jefferies Financial Group reissued a "buy" rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and a consensus price target of $619.41.
View Our Latest Report on TMO
Insider Buying and Selling at Thermo Fisher Scientific
In other news, EVP Michael D. Shafer sold 25,500 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares in the company, valued at $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer directly owned 2,966 shares of the company's stock, valued at $1,734,546.46. This represents a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 52,053 shares of company stock valued at $30,643,589 over the last three months. 0.33% of the stock is owned by insiders.
Thermo Fisher Scientific Stock Down 0.0%
Shares of Thermo Fisher Scientific stock opened at $588.17 on Monday. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $643.99. The firm has a market capitalization of $217.48 billion, a PE ratio of 31.64, a price-to-earnings-growth ratio of 2.39 and a beta of 0.84. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The stock's fifty day moving average is $529.37 and its 200-day moving average is $508.75.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific's revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter last year, the company posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.
Thermo Fisher Scientific Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.11%.
Thermo Fisher Scientific Profile
(
Free Report)
Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Read More
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
